TY - JOUR
T1 - The Landmark Series
T2 - Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer
AU - Leon-Ferre, Roberto A.
AU - Hieken, Tina J.
AU - Boughey, Judy C.
N1 - Funding Information:
This publication was supported in part by CTSA grant number KL2 TR002379 from the National Center for Advancing Translational Science (NCATS), and the Mayo Clinic Breast Cancer SPORE Grant P50 CA116201, Career Enhancement Program, from the National Institutes of Health (NIH). The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.
Funding Information:
Roberto Leon Ferre has received travel support from Immunomedics, and Tina Hieken has received unrelated research funding from Genentech. Judy C. Boughey has received unrelated research funding from Eli Lilly.
Publisher Copyright:
© 2021, Society of Surgical Oncology.
PY - 2021/4
Y1 - 2021/4
N2 - While historically breast cancer has been treated with primary surgery followed by adjuvant therapy, the delivery of systemic therapy in the neoadjuvant setting has become increasingly common, especially for triple-negative and HER2-positive breast cancer. The initial motivations for pursuing neoadjuvant chemotherapy (NAC) were decreasing the tumor burden in the breast and axilla to enable de-escalation of surgery, and use the strategy to advance drug development. While these remain of interest, recent trials have additionally demonstrated survival advantages from escalation of systemic treatment in patients with residual disease, and new studies are testing de-escalation of systemic therapy based on pathologic response. Thus, response information to NAC has become pivotal to guide adjuvant treatment recommendations, and has resulted in NAC being the preferred approach for most HER2-positive and triple-negative breast cancers. Herein, we review select landmark trials that have paved the way for the use of chemotherapy in the neoadjuvant setting for breast cancer.
AB - While historically breast cancer has been treated with primary surgery followed by adjuvant therapy, the delivery of systemic therapy in the neoadjuvant setting has become increasingly common, especially for triple-negative and HER2-positive breast cancer. The initial motivations for pursuing neoadjuvant chemotherapy (NAC) were decreasing the tumor burden in the breast and axilla to enable de-escalation of surgery, and use the strategy to advance drug development. While these remain of interest, recent trials have additionally demonstrated survival advantages from escalation of systemic treatment in patients with residual disease, and new studies are testing de-escalation of systemic therapy based on pathologic response. Thus, response information to NAC has become pivotal to guide adjuvant treatment recommendations, and has resulted in NAC being the preferred approach for most HER2-positive and triple-negative breast cancers. Herein, we review select landmark trials that have paved the way for the use of chemotherapy in the neoadjuvant setting for breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=85099742044&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099742044&partnerID=8YFLogxK
U2 - 10.1245/s10434-020-09480-9
DO - 10.1245/s10434-020-09480-9
M3 - Article
C2 - 33486641
AN - SCOPUS:85099742044
VL - 28
SP - 2111
EP - 2119
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
SN - 1068-9265
IS - 4
ER -